SCHEMBL2955899

SCHEMBL2955899

NC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADORA3 P0DMS8 3/20 0.38
ADORA2A P29274 3/20 0.38
ADORA1 P30542 3/20 0.38
IDO1 P14902 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958575 0.92 CDK4 (0.38) CSF1RNPC1RAB9ATDP1IDO1
Ammonia Solution, Strong SCHEMBL2960210 0.90 NPC1 (0.39) NPC1RAB9ACTDSP1RXFP1TDP1
SCHEMBL2952198 0.86 CSF1R (0.39) CSF1RMAPTMEN1KMT2AFPR2
SCHEMBL2959765 0.86 MAPT (0.42) CSF1RNPC1RAB9AIDO1MAPT
SCHEMBL2949772 0.85 ALDH1A1 (0.43) CSF1RNPC1RAB9AMAPTTP53
SCHEMBL2958030 0.85 ALDH1A1 (0.42) NPC1RAB9AMAPTTP53ALDH1A1
SCHEMBL2958676 0.85 ALDH1A1 (0.47) CSF1RNPC1RAB9AMAPTTP53
SCHEMBL2955772 0.84 CYP3A4 (0.39) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL2958025 0.84 DHODH (0.37) CSF1RRAB9AADORA3ADORA2AADORA1
SCHEMBL2949616 0.84 DRD4 (0.40) CSF1RNPC1RAB9ACTDSP1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CSF1R 412/4885NPC1 2692/4885RAB9A 3150/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CSF1R 328/4885NPC1 2803/4885RAB9A 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.